Free Trial
OTCMKTS:GNMSF

Genmab A/S (GNMSF) Stock Price, News & Analysis

Genmab A/S logo
$214.95 +2.40 (+1.13%)
As of 07/11/2025 11:55 AM Eastern

About Genmab A/S Stock (OTCMKTS:GNMSF)

Key Stats

Today's Range
$214.95
$214.95
50-Day Range
$188.80
$224.30
52-Week Range
$170.00
$292.80
Volume
2 shs
Average Volume
42 shs
Market Capitalization
$14.20 billion
P/E Ratio
12.19
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Genmab A/S Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
5th Percentile Overall Score

GNMSF MarketRank™: 

Genmab A/S scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Genmab A/S.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Genmab A/S is 12.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.84.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Genmab A/S is 12.19, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.21.

  • Price to Book Value per Share Ratio

    Genmab A/S has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Genmab A/S's valuation and earnings.
  • Percentage of Shares Shorted

    0.13% of the float of Genmab A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Genmab A/S has a short interest ratio ("days to cover") of 833, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Genmab A/S has recently increased by 86.35%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Genmab A/S does not currently pay a dividend.

  • Dividend Growth

    Genmab A/S does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.13% of the float of Genmab A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Genmab A/S has a short interest ratio ("days to cover") of 833, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Genmab A/S has recently increased by 86.35%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Genmab A/S has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Genmab A/S this week, compared to 2 articles on an average week.
Receive GNMSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

GNMSF Stock News Headlines

Genmab Completes Share Buy-back Program
This Cold War “Accident” Could Unleash New $100 Trillion AI Boom
Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
See More Headlines

GNMSF Stock Analysis - Frequently Asked Questions

Genmab A/S's stock was trading at $207.38 at the beginning of the year. Since then, GNMSF shares have increased by 3.7% and is now trading at $214.95.

Genmab A/S (OTCMKTS:GNMSF) posted its quarterly earnings data on Thursday, May, 8th. The company reported $3.05 EPS for the quarter, topping analysts' consensus estimates of $1.88 by $1.17. The business had revenue of $765.14 million for the quarter, compared to analysts' expectations of $761.09 million. Genmab A/S had a trailing twelve-month return on equity of 19.23% and a net margin of 35.11%.

Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/08/2025
Today
7/12/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:GNMSF
CIK
1434265
Employees
2,682
Year Founded
1999

Profitability

EPS (Trailing Twelve Months)
$17.63
Trailing P/E Ratio
12.19
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$1.14 billion
Net Margins
35.11%
Pretax Margin
40.96%
Return on Equity
19.23%
Return on Assets
15.44%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.34
Quick Ratio
5.32

Sales & Book Value

Annual Sales
$3.12 billion
Price / Sales
4.55
Cash Flow
$15.35 per share
Price / Cash Flow
14.00
Book Value
$80.53 per share
Price / Book
2.67

Miscellaneous

Outstanding Shares
66,075,000
Free Float
65,057,000
Market Cap
$14.20 billion
Optionable
Not Optionable
Beta
0.91

Social Links

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (OTCMKTS:GNMSF) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners